Y-mAbs Therapeutics, Inc.

The current price of YMAB is 14.84 USD — it has decreased by 2.94% in the past 24 hours.

Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Y-mAbs Therapeutics, Inc. stocks are traded under the ticker YMAB.

Y-mAbs Therapeutics, Inc. is going to release the next earnings report on May 10, 2024. Keep track of upcoming events with our Earnings Calendar.

YMAB stock is 8.26% volatile and has beta coefficient of 0.45. Check out the list of the most volatile stocks — is Y-mAbs Therapeutics, Inc. there?

YMAB earnings for the last quarter are −0.18 USD per share, whereas the estimation was −0.19 USD resulting in a 4.15% surprise. The estimated earnings for the next quarter are −0.20 USD per share. See more details about Y-mAbs Therapeutics, Inc. earnings.

Y-mAbs Therapeutics, Inc. revenue for the last quarter amounts to ‪19.95 M‬ USD despite the estimated figure of ‪20.97 M‬ USD. In the next quarter revenue is expected to reach ‪20.95 M‬ USD.

Yes, you can track Y-mAbs Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.

YMAB stock has fallen by 0.60% compared to the previous week, the month change is a 7.31% fall, over the last year Y-mAbs Therapeutics, Inc. has showed a 157.64% increase.

Today Y-mAbs Therapeutics, Inc. has the market capitalization of ‪649.65 M‬, it has increased by 0.13% over the last week.

No, YMAB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.

Like other stocks, YMAB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Y-mAbs Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.

YMAB reached its all-time high on Nov 9, 2020 with the price of 55.22 USD, and its all-time low was 2.70 USD and was reached on Mar 24, 2023.
See other stocks reaching their highest and lowest prices.

As of Apr 26, 2024, the company has 100.00 employees. See our rating of the largest employees — is Y-mAbs Therapeutics, Inc. on this list?

Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Y-mAbs Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Y-mAbs Therapeutics, Inc. stock shows the buy signal. See more of Y-mAbs Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.

We've gathered analysts' opinions on Y-mAbs Therapeutics, Inc. future price: according to them, YMAB price has a max estimate of 26.00 USD and a min estimate of 12.00 USD. Read a more detailed Y-mAbs Therapeutics, Inc. forecast: see what analysts think of Y-mAbs Therapeutics, Inc. and suggest that you do with its stocks.

EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Y-mAbs Therapeutics, Inc. EBITDA is ‪−24.94 M‬ USD, and current EBITDA margin is −24.12%. See more stats in Y-mAbs Therapeutics, Inc. financial statements.